Dr. Isaac Yi Kim Profile

Dr. Isaac Yi Kim

at Rutgers Cancer Institute of New Jersey

SPIE Involvement:

Author

Publications (1)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 4 March 2019 Presentation

Surface-enhancement Raman scattering of urine for prostate cancer risk assessment (Conference Presentation)

Yiwei Ma, Liu Kai, Isaac Kim, Henry Du

Proceedings Volume 10891, 1089111 (2019) https://doi.org/10.1117/12.2510265

KEYWORDS: Prostate cancer, Raman scattering, Principal component analysis, Statistical analysis, Raman spectroscopy, Prostate

Read Abstract +

Prostate cancer is a heterogenous disease that has a varied range from indolent to highly aggressiveness. The routinely used biomarker, Prostate Specific Antigen (PSA), is controversial due to over-diagnosis. A new approach is urgently needed to discriminate the indolent and lethal prostate cancer. We report the measurements of patient urine using surface-enhancement Raman scattering (SERS) as a potential means of differentiating aggressive and indolent prostate cancer types. To this end, urine samples from twenty prostate cancer patients with known clinical outcome are investigated in this study, with ten in each of the two groups: aggressive and indolent. SERS measurements, ten for each sample, are carried out in blind without revealing any clinical details to the investigators. Principal component analysis (PCA) and linear discriminant analysis (LDA) are used to statistically analyze the large number of Raman spectra to identify and classify the specific Raman features potentially associated with aggressive and indolent prostate cancer types. The experimental classifications are compared with the clinical outcome of the prostate cancer patients to demonstration the potential of SERS as an alternative method for patient screening and decision-making for the optimal treatment strategy.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years